ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

4.79
-0.06
(-1.24%)
Closed November 05 4:00PM
4.805
0.015
( 0.31% )
Pre Market: 8:49AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.805
Bid
4.81
Ask
4.85
Volume
1,117
0.00 Day's Range 0.00
3.295 52 Week Range 6.75
Market Cap
Previous Close
4.79
Open
-
Last Trade
11
@
4.83
Last Trade Time
08:38:03
Financial Volume
-
VWAP
-
Average Volume (3m)
564,491
Shares Outstanding
58,289,808
Dividend Yield
-
PE Ratio
111.40
Earnings Per Share (EPS)
0.04
Revenue
192.64M
Net Profit
2.51M

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $4.79. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.295 to $ 6.75.

Vanda Pharmaceuticals currently has 58,289,808 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $279.21 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 111.40.

VNDA Latest News

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024...

Ericsson Shares Surge 7% on Strong Earnings, Nvidia Drops 2%, Google Invests in Nuclear Power for AI

Ericsson (NASDAQ:ERIC) – Ericsson reported better-than-expected profits, driven by a rebound in 5G equipment demand in North America. Net sales fell 4% to $5.92 billion but surpassed...

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, Oct. 14, 2024 Board Has Determined That...

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis PR Newswire WASHINGTON, Sept. 19, 2024 WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference PR Newswire WASHINGTON, Sept. 11, 2024 WASHINGTON, Sept. 11, 2024 /PRNewswire/ --Β Vanda...

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference PR Newswire WASHINGTON, Sept. 4, 2024 WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Vanda...

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference PR Newswire WASHINGTON, Aug. 29, 2024 WASHINGTON, Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.14533.118226495274.65974.94.564960504.73690898CS
40.3056.777777777784.55.34.356915974.75495404CS
12-0.305-5.96868884545.115.5254.355644914.88587709CS
26-0.195-3.956.754.358528255.46510606CS
520.2655.837004405294.546.753.29512473934.82804622CS
156-13.125-73.201338538817.9318.453.2958328606.59778698CS
260-8.695-64.407407407413.521.86273.2957150918.87253903CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SONNSonnet BioTherapeutics Holdings Inc
$ 11.79
(180.05%)
2.39M
DATSDatChat Inc
$ 3.51
(96.09%)
30.71M
STRSStratus Properties Inc
$ 36.71
(58.92%)
67
GDEVGDEV Inc
$ 40.98
(49.02%)
227
AREBAmerican Rebel Holdings Inc
$ 4.00
(43.37%)
15.69M
SMCXDefiance Daily Target 2X Long SMCI ETF
$ 1.53
(-36.25%)
4.17M
ZCARZoomcar Holdings Inc
$ 8.49
(-35.68%)
248.96k
VSTEVast Renewable Ltd
$ 3.4899
(-34.89%)
1.11M
TNGXTango Therapeutics Inc
$ 3.4499
(-33.40%)
192.98k
WCTWellchange Holdings Company Limited
$ 5.30
(-30.45%)
136.83k
ELABElevai Labs Inc
$ 0.0223
(4.21%)
39.49M
DJTTrump Media and Technology Group Corporation
$ 43.121
(27.05%)
38.11M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.91
(24.46%)
38.05M
DATSDatChat Inc
$ 3.51
(96.09%)
30.71M
TSLATesla Inc
$ 282.23
(12.25%)
17.03M

VNDA Discussion

View Posts
Zilla Zilla 3 weeks ago
WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
VNDA under $7
πŸ‘οΈ0
harry crumb harry crumb 4 months ago
Watching this closely
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
VNDA under $10
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
Over $6
πŸ‘οΈ0
tw0122 tw0122 5 months ago
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
πŸ‘οΈ0
harry crumb harry crumb 6 months ago
Gonna be a winner. Patience
πŸ‘οΈ0
harry crumb harry crumb 6 months ago
Over 5$!
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
VNDA under $5
πŸ‘οΈ0
harry crumb harry crumb 6 months ago
Let er rip $$$$$$$$
πŸ‘οΈ0
Tiger Money Tiger Money 7 months ago
Agreed. This could double quickly
πŸ‘οΈ0
philaya philaya 7 months ago
got this today...
very good trades.
πŸ‘οΈ0
harry crumb harry crumb 7 months ago
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
πŸ‘οΈ0
morokoy morokoy 7 months ago
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
πŸ‘οΈ0
morokoy morokoy 7 months ago
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
πŸ‘οΈ0
harry crumb harry crumb 7 months ago
Minimum 8$ imo
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 7 months ago
Probably...but I took it at 5.49
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
Will it grow legs after 9:30
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA Good post, Laster.
https://www.futurepak.com/
πŸ‘οΈ0
Laster Laster 7 months ago
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
VNDA In 5.12. Let's see, said the blind man.
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
πŸ‘οΈ0
MiamiGent MiamiGent 7 months ago
What's the news?
πŸ‘οΈ0
Awl416 Awl416 7 months ago
Damn
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
Will it grow legs after 9:30
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
Will it grow legs after 9:30
πŸ‘οΈ0
tknuncle tknuncle 9 months ago
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
πŸ‘οΈ0
weedtrader420 weedtrader420 9 months ago
FDA Approve
πŸ‘οΈ0
Triple nickle Triple nickle 11 months ago
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 2 years ago
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the β€œComplaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
πŸ‘οΈ0
Peepson Peepson 4 years ago
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

πŸ‘οΈ0
otcmoneydoubler otcmoneydoubler 4 years ago
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
πŸ‘οΈ0
Peepson Peepson 4 years ago
Yo, does anyone still follow this board. I might have some interesting dd to share.
πŸ‘οΈ0
bezen bezen 8 years ago
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
πŸ‘οΈ0
Coz Mabluda Coz Mabluda 8 years ago
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

πŸ‘οΈ0
ClearlyStocks ClearlyStocks 8 years ago
VNDA $16.74
πŸ‘οΈ0
ClearlyStocks ClearlyStocks 8 years ago
$VNDA $16 from $14 now
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock